• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用PROMISE标准,对[镓]镓-PSMA-I&T PET/CT进行评估,并对前列腺特异性抗原复发患者的骨盆进行额外的晚期扫描。

Evaluation of [ Ga]Ga-PSMA-I&T PET/CT with additional late scans of the pelvis in prostate-specific antigen recurrence using the PROMISE criteria.

作者信息

Koehler Daniel, Sauer Markus, Karimzadeh Amir, Apostolova Ivayla, Klutmann Susanne, Adam Gerhard, Knipper Sophie, Maurer Tobias, Berliner Christoph

机构信息

Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.

Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

出版信息

EJNMMI Res. 2022 Oct 9;12(1):66. doi: 10.1186/s13550-022-00938-3.

DOI:10.1186/s13550-022-00938-3
PMID:36210356
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9548463/
Abstract

BACKGROUND

PSMA PET/CT is the recommended imaging test in cases with prostate-specific antigen (PSA) recurrence after primary therapy of prostate cancer (PCa). However, imaging protocols remain a topic of active research. The aim of the presented study was to examine the impact of additional late scans of the pelvis in [ Ga]Ga-PSMA-I&T PET/CT of patients with rising PSA after prostatectomy.

METHODS

A total of 297 patients (median PSA 0.35 ng/ml, interquartile range (IQR) 0.2-0.8) who underwent early whole-body [ Ga]Ga-PSMA-I&T PET/CT (median dose 141 MBq, IQR 120-163; median 86 min, IQR 56-107) and additional late scans of the pelvis (median 180 min, IQR 170-191) were investigated retrospectively. Early and late images were staged separately according to the PROMISE criteria and compared with a final consensus of both. Standardized uptake values were analyzed for early and late scans.

RESULTS

One hundred and thirty-four (45.1%) [ Ga]Ga-PSMA-I&T PET/CT showed evidence of recurrent PCa (114/38.4% early, 131/44.1% late). Of 195 lesions, 144 (73.8%) were identified correctly on early scans. 191 (97.9%) lesions were detected on late imaging. The lesion SUVmax (median 3.4, IQR 0.4-6.5 vs. median 3.9, IQR 2.6-8.2) as well as the SUVmax to background ratio (median 9.4, IQR 1.7-19.1 vs. median 15.5, IQR 9.6-34.1) increased significantly between the imaging time points (p < 0.01, respectively). Compared to the final consensus, the miTNM-staging of early scans changed in 58 (19.5%) cases. Of these, 31 patients (10.4%) with negative early scans (T0 N0 M0) were upstaged. Twenty-seven (9.1%) patients with PCa characteristic lesions on early imaging (> T0 N0 M0) were up- and/or downstaged. In 4 (1.3%) cases, PCa-related lesions were only detectable on early PET/CT leading to upstagings of late imaging.

CONCLUSIONS

Additional late scans of the pelvis in [ Ga]Ga-PSMA-I&T PET/CT detected more lesions and an increasing contrast compared to early imaging. This influenced the final miTNM-staging substantially.

摘要

背景

对于前列腺癌(PCa)初次治疗后出现前列腺特异性抗原(PSA)复发的病例,PSMA PET/CT是推荐的影像学检查。然而,成像方案仍是一个活跃的研究课题。本研究的目的是探讨在前列腺切除术后PSA升高的患者中,在[镓]Ga-PSMA-I&T PET/CT检查中增加骨盆晚期扫描的影响。

方法

对297例患者(中位PSA 0.35 ng/ml,四分位间距(IQR)0.2 - 0.8)进行回顾性研究,这些患者接受了早期全身[镓]Ga-PSMA-I&T PET/CT检查(中位剂量141 MBq,IQR 120 - 163;中位86分钟,IQR 56 - 107)以及额外的骨盆晚期扫描(中位180分钟,IQR 170 - 191)。早期和晚期图像分别根据PROMISE标准进行分期,并与两者的最终共识进行比较。分析早期和晚期扫描的标准化摄取值。

结果

134例(45.1%)[镓]Ga-PSMA-I&T PET/CT显示有PCa复发证据(早期114例/38.4%,晚期131例/44.1%)。在195个病灶中,早期扫描正确识别出144个(73.8%)。晚期成像检测到191个(97.9%)病灶。在不同成像时间点之间,病灶SUVmax(中位值3.4,IQR 0.4 - 6.5对比中位值3.9,IQR 2.6 - 8.2)以及SUVmax与背景比值(中位值9.4,IQR 1.7 - 19.1对比中位值15.5,IQR 9.6 - 34.1)均显著增加(p均<0.01)。与最终共识相比,早期扫描的miTNM分期在58例(19.5%)病例中发生了变化。其中,31例早期扫描为阴性(T0 N0 M0)的患者(10.4%)被上调分期。27例(9.1%)早期成像有PCa特征性病灶(>T0 N0 M0)的患者被上调和/或下调分期。在4例(1.3%)病例中,PCa相关病灶仅在早期PET/CT上可检测到,导致晚期成像上调分期。

结论

与早期成像相比,在[镓]Ga-PSMA-I&T PET/CT中增加骨盆晚期扫描可检测到更多病灶且对比度增加。这对最终的miTNM分期有重大影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f748/9548463/e189b810142d/13550_2022_938_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f748/9548463/9add22d3eb24/13550_2022_938_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f748/9548463/1866133dba80/13550_2022_938_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f748/9548463/3764d2fabdad/13550_2022_938_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f748/9548463/e189b810142d/13550_2022_938_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f748/9548463/9add22d3eb24/13550_2022_938_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f748/9548463/1866133dba80/13550_2022_938_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f748/9548463/3764d2fabdad/13550_2022_938_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f748/9548463/e189b810142d/13550_2022_938_Fig4_HTML.jpg

相似文献

1
Evaluation of [ Ga]Ga-PSMA-I&T PET/CT with additional late scans of the pelvis in prostate-specific antigen recurrence using the PROMISE criteria.使用PROMISE标准,对[镓]镓-PSMA-I&T PET/CT进行评估,并对前列腺特异性抗原复发患者的骨盆进行额外的晚期扫描。
EJNMMI Res. 2022 Oct 9;12(1):66. doi: 10.1186/s13550-022-00938-3.
2
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
3
Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.使用[68]Ga-PSMA-11进行早期PET成像可提高生化复发的前列腺癌患者局部复发的检出率。
Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1647-1655. doi: 10.1007/s00259-017-3743-z. Epub 2017 Jun 6.
4
Combined Early and Late [Ga]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels.早期和晚期联合[Ga]PSMA-HBED-CC PET 扫描可提高低 PSA 水平前列腺癌生化复发时的病灶检出率。
Mol Imaging Biol. 2019 Jun;21(3):558-566. doi: 10.1007/s11307-018-1263-2.
5
Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.在 PSA 水平低于 1.0ng/ml 的 270 例患者中,Ga-PSMA-11 PET/CT 对前列腺癌根治术后生化复发的定位:对挽救性放疗计划的影响。
J Nucl Med. 2018 Feb;59(2):230-237. doi: 10.2967/jnumed.117.201749. Epub 2017 Nov 9.
6
(68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.(68)镓-PSMA-11动态PET/CT成像在前列腺癌生化复发中的应用
Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1288-99. doi: 10.1007/s00259-015-3302-4. Epub 2016 Jan 12.
7
Dual-Time Point [Ga]Ga-PSMA-11 PET/CT Hybrid Imaging for Staging and Restaging of Prostate Cancer.双时间点[镓]镓-PSMA-11 PET/CT融合成像用于前列腺癌的分期及再分期
Cancers (Basel). 2020 Sep 28;12(10):2788. doi: 10.3390/cancers12102788.
8
The Clinical Impact of Additional Late PET/CT Imaging with Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer.镓标记的PSMA-11(HBED-CC)额外晚期PET/CT成像在前列腺癌诊断中的临床影响
J Nucl Med. 2017 May;58(5):750-755. doi: 10.2967/jnumed.116.183483. Epub 2017 Jan 6.
9
Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.Ga 标记前列腺特异性膜抗原配体正电子发射断层扫描/计算机断层扫描在前列腺癌中的应用:系统评价和荟萃分析。
Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15.
10
Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.镓-PSMA-11 PET/CT 在复发性前列腺癌中的应用:根治性治疗后 PSA 失败不同临床阶段的疗效。
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):31-39. doi: 10.1007/s00259-018-4189-7. Epub 2018 Oct 22.

引用本文的文献

1
Impact of delayed pelvic imaging on the staging of biochemical recurrence in prostate cancer patients using [F]DCFPYL PET/CT: a retrospective evaluation.延迟盆腔成像对使用[F]DCFPYL PET/CT的前列腺癌患者生化复发分期的影响:一项回顾性评估
EJNMMI Rep. 2025 Feb 1;9(1):5. doi: 10.1186/s41824-025-00238-8.
2
Comparative analysis of positron emitters for theranostic applications based on small bioconjugates highlighting Sc, Cu and Ti.基于小型生物共轭物对用于诊疗应用的正电子发射体进行比较分析,重点关注钪、铜和钛。
EJNMMI Phys. 2024 Nov 22;11(1):98. doi: 10.1186/s40658-024-00699-z.
3
"One Method to Label Them All": A Single Fully Automated Protocol for GMP-Compliant Ga Radiolabeling of PSMA-11, Transposable to PSMA-I&T and PSMA-617.

本文引用的文献

1
Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery.寡复发性前列腺癌患者队列研究:通过前列腺特异性膜抗原放射性引导手术进行挽救性淋巴结清扫术治疗患者的肿瘤学结局
Eur Urol. 2023 Jan;83(1):62-69. doi: 10.1016/j.eururo.2022.05.031. Epub 2022 Jun 17.
2
Is there a diagnostic benefit of late-phase abdomino-pelvic PET/CT after urination as part of whole-body  Ga-PSMA-11 PET/CT for restaging patients with biochemical recurrence of prostate cancer after radical prostatectomy?对于前列腺癌根治术后生化复发患者进行再分期的全身镓 PSMA - 11 PET/CT检查时,排尿后进行晚期腹盆腔PET/CT检查是否具有诊断益处?
EJNMMI Res. 2022 Mar 4;12(1):12. doi: 10.1186/s13550-022-00885-z.
3
“一法通用”:一种符合 GMP 标准的 PSMA-11 全自动伽马放射性标记方法,可推广至 PSMA-I&T 和 PSMA-617。
Curr Radiopharm. 2024;17(3):285-301. doi: 10.2174/0118744710293461240219111852.
4
PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score.从影像解读到治疗反应评估的按癌症类型划分的PET标准:超越FDG PET评分
Life (Basel). 2023 Feb 22;13(3):611. doi: 10.3390/life13030611.
Event-free survival after  Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapy.复发的激素敏感型前列腺癌(HSPC)患者在适合挽救性治疗的情况下,经 Ga-PSMA-11 PET/CT 检查后无事件生存。
Eur J Nucl Med Mol Imaging. 2022 Jul;49(9):3257-3268. doi: 10.1007/s00259-022-05741-9. Epub 2022 Feb 26.
4
Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.根治性前列腺切除术后 PSMA-PET/CT 引导挽救性放疗后淋巴结复发的结果。
Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1417-1428. doi: 10.1007/s00259-021-05557-z. Epub 2021 Oct 10.
5
PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study.PSMA PET 验证了欧洲泌尿外科学会生化复发风险组更高的转移疾病发生率:一项国际多中心研究。
J Nucl Med. 2022 Jan;63(1):76-80. doi: 10.2967/jnumed.121.262821. Epub 2021 Oct 7.
6
Diagnostic Performance and Clinical Impact of Ga-PSMA-11 PET/CT Imaging in Early Relapsed Prostate Cancer After Radical Therapy: A Prospective Multicenter Study (IAEA-PSMA Study).镓-PSMA-11 PET/CT 成像在根治性治疗后早期复发前列腺癌中的诊断性能和临床影响:一项前瞻性多中心研究(IAEA-PSMA 研究)。
J Nucl Med. 2022 Feb;63(2):240-247. doi: 10.2967/jnumed.120.261886. Epub 2021 Jul 2.
7
Pharmacokinetic studies of [ Ga]Ga-PSMA-11 in patients with biochemical recurrence of prostate cancer: detection, differences in temporal distribution and kinetic modelling by tissue type.[68Ga]Ga-PSMA-11 药代动力学研究在前列腺癌生化复发患者中的应用:基于组织类型的检测、时相分布差异和动力学建模。
Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4472-4482. doi: 10.1007/s00259-021-05420-1. Epub 2021 Jun 10.
8
Combination of Forced Diuresis with Additional Late Imaging in Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake.镓-PSMA-11 PET/CT 中联合强制利尿和后期显像:对病灶显示和放射性示踪剂摄取的影响。
J Nucl Med. 2021 Sep 1;62(9):1252-1257. doi: 10.2967/jnumed.120.257741. Epub 2021 Feb 5.
9
Dual-Time Point [Ga]Ga-PSMA-11 PET/CT Hybrid Imaging for Staging and Restaging of Prostate Cancer.双时间点[镓]镓-PSMA-11 PET/CT融合成像用于前列腺癌的分期及再分期
Cancers (Basel). 2020 Sep 28;12(10):2788. doi: 10.3390/cancers12102788.
10
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.晚期前列腺癌:AUA/ASTRO/SUO 指南 PART I.
J Urol. 2021 Jan;205(1):14-21. doi: 10.1097/JU.0000000000001375. Epub 2020 Sep 22.